174 related articles for article (PubMed ID: 9654265)
1. Rhabdomyolysis due to interaction of simvastatin with mibefradil.
Schmassmann-Suhijar D; Bullingham R; Gasser R; Schmutz J; Haefeli WE
Lancet; 1998 Jun; 351(9120):1929-30. PubMed ID: 9654265
[No Abstract] [Full Text] [Related]
2. Case report: rhabdomyolysis induced by mibefradil in a patient treated with cyclosporine and simvastatin.
Wombolt DG; Jackson A; Punn R; Smith S; McCune TR; Williams PB
J Clin Pharmacol; 1999 Mar; 39(3):310-2. PubMed ID: 10073331
[No Abstract] [Full Text] [Related]
3. Mibefradil withdrawn from the market.
Billups SJ; Carter BL
Ann Pharmacother; 1998; 32(7-8):841. PubMed ID: 9681103
[No Abstract] [Full Text] [Related]
4. [Induction of bradycardia by mibefradil in antihypertensive combination therapy].
Wagner J; Ritz E
Dtsch Med Wochenschr; 1998 Apr; 123(17):547. PubMed ID: 9601479
[No Abstract] [Full Text] [Related]
5. Mibefradil (posicor).
Giles TD
Compr Ther; 1997 Nov; 23(11):761-3. PubMed ID: 9360806
[No Abstract] [Full Text] [Related]
6. Mibefradil: a new class of calcium-channel antagonists.
Billups SJ; Carter BL
Ann Pharmacother; 1998 Jun; 32(6):659-71. PubMed ID: 9640486
[TBL] [Abstract][Full Text] [Related]
7. Good news for experimental concept but bad news for clinically effective therapy.
Reimer KA; Califf RM
Circulation; 1999 Jan; 99(2):198-200. PubMed ID: 9892582
[No Abstract] [Full Text] [Related]
8. [Introducing mibefradil--a new T-calcium channel blocker].
Internist (Berl); 1997 Dec; 38(12 Suppl Mibefradil):1-4. PubMed ID: 9437250
[No Abstract] [Full Text] [Related]
9. [Mibefradil: a new class calcium inhibitor].
Internist (Berl); 1996 Oct; 37(10 Suppl Mibefradil):1-8. PubMed ID: 9402420
[No Abstract] [Full Text] [Related]
10. The withdrawal of mibefradil (Posicor).
Griffin JP
Adverse Drug React Toxicol Rev; 1998; 17(2-3):59-60. PubMed ID: 9838964
[No Abstract] [Full Text] [Related]
11. Serious interaction between mibefradil and tacrolimus.
Krähenbühl S; Menafoglio A; Giostra E; Gallino A
Transplantation; 1998 Oct; 66(8):1113-5. PubMed ID: 9808502
[TBL] [Abstract][Full Text] [Related]
12. [The pharmacological and clinical outlook for mibefradil--a new selective T-type calcium channel antagonist].
Eliseev OM
Ter Arkh; 1998; 70(8):87-8. PubMed ID: 9841457
[No Abstract] [Full Text] [Related]
13. Comment: mibefradil, a new class of calcium-channel antagonists.
Otterman S
Ann Pharmacother; 1998 Dec; 32(12):1372. PubMed ID: 9876826
[No Abstract] [Full Text] [Related]
14. [Progress in new cardiovascular treatment. Background discussion and interview in the Basel Roche Research Center].
Keil U
Fortschr Med; 1996 Feb; 114(4):39-40. PubMed ID: 8852686
[No Abstract] [Full Text] [Related]
15. Pharmacologic and clinical perspectives on mibefradil: a new T-channel selective calcium antagonist: introduction.
Giles TD
Am J Cardiol; 1997 Aug; 80(4B):1C-3C. PubMed ID: 9286847
[No Abstract] [Full Text] [Related]
16. Simvastatin-induced rhabdomyolysis following cyclosporine treatment for uveitis.
Lasocki A; Vote B; Fassett R; Zamir E
Ocul Immunol Inflamm; 2007; 15(4):345-6. PubMed ID: 17763133
[TBL] [Abstract][Full Text] [Related]
17. [Mibefradil opens up a new class of calcium antagonists. Glasgow, 23 June 1996].
Dtsch Med Wochenschr; 1996 Sep; 121(39 Suppl):1-4. PubMed ID: 9212757
[No Abstract] [Full Text] [Related]
18. [Current therapy of coronary heart disease. Conservative measures].
Stephan S
Internist (Berl); 1998 Sep; 39(9):1001-2. PubMed ID: 9788131
[No Abstract] [Full Text] [Related]
19. Long-term antianginal and antiischemic effects of mibefradil, the novel T-type calcium channel blocker: a multicenter, double-blind, placebo-controlled, randomized comparison with sustained-release diltiazem.
Davies GJ; Kobrin I; Caspi A; Reisin LH; de Albuquerque DC; Armagnijan D; Coelho OR; Schneeweiss A
Am Heart J; 1997 Aug; 134(2 Pt 1):220-8. PubMed ID: 9313601
[TBL] [Abstract][Full Text] [Related]
20. Mibefradil, a pharmacologically distinct calcium antagonist.
Ernst ME; Kelly MW
Pharmacotherapy; 1998; 18(3):463-85. PubMed ID: 9620098
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
